Response to 'Adverse cardiac outcomes in patients with chronic myeloid leukaemia treated with tyrosine kinase inhibitors'

Heart. 2021 Oct;107(20):1680-1681. doi: 10.1136/heartjnl-2021-319415. Epub 2021 Jun 30.

Authors

Darryl Leong¹, Christopher Hillis², Nazanin Aghel³, Gregory Pond², Hsien Seow²

Affiliations

¹ Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada leongd@phri.ca.
² Department of Oncology, McMaster University, Hamilton, Ontario, Canada.
³ Department of Medicine, McMaster University, Hamilton, Ontario, Canada.

PMID: 34193463
DOI: 10.1136/heartjnl-2021-319415

No abstract available

Keywords: epidemiology.

Publication types

Letter
Comment

MeSH terms

Chronic Disease
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive* / drug therapy
Protein Kinase Inhibitors / adverse effects

Substances

Protein Kinase Inhibitors